FDA’s Regulatory Flexibility On Display In Review Of Innovative Agents

By Bridget Silverman / Email the Author / Pharmaceutical Approvals Monthly December 2011, Vol. 16, No. 12
Drug Review Profile / Word Count: 1945 / Article # 06111201007

Executive Summary

Regulatory flexibility is the backbone of FDA’s success in efficiently reviewing new drugs and biologics, especially on the frontiers of unmet medical needs, Pharmaceutical Approvals Monthly’s 2011 series of drug review profiles shows.

Purchase this Article

$85.00 Buy Now

For $85.00, purchase this 1945-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: FDA’s Regulatory Flexibility On Display In Review Of Innovative Agents

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Pharmaceutical Approvals Monthly will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

FDA’s Regulatory Flexibility On Display In Review Of Innovative Agents

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 6

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article